Mogrifiy completes Series A financing roundCell reprogramming specialist Mogrify Ltd has announced the second closing of its Series A financing of $17m, bringing the total raised to $33m in this round. more ➔
COVID-19 vaccine for poor countriesModerna Inc. has signed a COVID-19 vaccine supply agreement with vaccination alliance Gavi. more ➔
ADCendo ApS raises €51m in Series A financingDanish ADCendo ApS will use the funds from a Series A investment to advance Antibody-Drug Conjugates (ADCs) entering cancer cells through endocytic receptors. more ➔
DNA Script bags DARPA fundingDNA Script will receive a $5m DARPA grant as part of the agency’s Nucleic Acids On-Demand World-Wide Program to prevent the next viral pandemic. more ➔
First malaria vaccine meets WHO efficacy criteriaResearchers at Novavax and from the University of Oxford reported an efficacy of 77% of their malaria vaccine, R21/Matrix-M from a Phase II trials in Burkina Faso. more ➔
European COVID-19 antibody enters Phase III testingGSK’s and Vir Therapeutics’ COVID-19 antibody treatment VIR-7831 has entered Phase III testing within the UK’s COVID-19 drug testing platform, AGILE more ➔
J&J starts European COVID-19 vaccine roll-outAfter a positive re-evaluation of J&J’s COVID-19 vaccine by the European Medicines Agency (EMA), J&J has re-started to ship 55 million doses to the EU. more ➔
Endeavour Medtech Growth II LP closes at $375mEndeavour Vision has announced the closing of its Heathtech fund Endeavour Medtech Growth II (EMG II) LP at US$375 million in capital commitments. more ➔
Record year for Swiss biotech industry The Swiss biotech industry experienced a record investment in the pandemic year 2020, according to the new Swiss Biotech Report. more ➔
EU orders 100 million additional doses from Biontech The European Union has exercised its option to order 100 million additional doses of BNT162b2 bringing its orders to 600 million doses at €14.70 per shot. more ➔
